Axovia Therapeutics gratefully announces receipt of a generous $1 million grant from A Race Against Blindness to propel its upcoming UK clinical trial for Bardet-Biedl Syndrome type 1 (BBS1). This crucial funding will support trial initiation, patient recruitment, and essential operations, accelerating the delivery of this breakthrough therapy to those living with childhood blindness due to faults in the BBS1 gene. With the support of our partners, Axovia strengthens its mission to halt retinal degeneration and transform the future for those impacted by this rare condition.
